The peritumoral brain zone in glioblastoma: where we are and where we are going
- PMID: 36300592
- PMCID: PMC10091804
- DOI: 10.1002/jnr.25134
The peritumoral brain zone in glioblastoma: where we are and where we are going
Abstract
Glioblastoma (GBM) is the most aggressive and invasive primary brain tumor. Current therapies are not curative, and patients' outcomes remain poor with an overall survival of 20.9 months after surgery. The typical growing pattern of GBM develops by infiltrating the surrounding apparent normal brain tissue within which the recurrence is expected to appear in the majority of cases. Thus, in the last decades, an increased interest has developed to investigate the cellular and molecular interactions between GBM and the peritumoral brain zone (PBZ) bordering the tumor tissue. The aim of this review is to provide up-to-date knowledge about the oncogenic properties of the PBZ to highlight possible druggable targets for more effective treatment of GBM by limiting the formation of recurrence, which is almost inevitable in the majority of patients. Starting from the description of the cellular components, passing through the illustration of the molecular profiles, we finally focused on more clinical aspects, represented by imaging and radiological details. The complete picture that emerges from this review could provide new input for future investigations aimed at identifying new effective strategies to eradicate this still incurable tumor.
Keywords: glioblastoma; multimodal imaging; peritumoral brain zone.
© 2022 The Authors. Journal of Neuroscience Research published by Wiley Periodicals LLC.
Conflict of interest statement
The authors have no relevant financial or nonfinancial interests to disclose.
Figures



References
-
- Abe, Y. , Matsumoto, S. , Kito, K. , & Ueda, N. (2000). Cloning and expression of a novel MAPKK‐like protein kinase, lymphokine‐activated killer T‐cell‐originated protein kinase, specifically expressed in the testis and activated lymphoid cells. Journal of Biological Chemistry, 275(28), 21525–21531. - PubMed
-
- Abrol, S. , Kotrotsou, A. , Hassan, A. , Elshafeey, N. , Hassan, I. , Idris, T. , el Salek, K. , Elakkad, A. , Alfaro, K. , Weathers, S. P. S. , Moron, F. E. , Huse, J. , Weinberg, J. S. , Heimberger, A. B. , Sawaya, R. , Kumar, A. J. , De Groot, J. F. , Law, M. , Zinn, P. , & Colen, R. R. (2017). Radiomic analysis of pseudo‐progression compared to true progression in glioblastoma patients: A large‐scale multi‐institutional study. American Society of Clinical Oncology, 35, vi162–vi163.
-
- Ahir, B. K. , Ozer, H. , Engelhard, H. H. , & Lakka, S. S. (2017). MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review. Critical Reviews in Oncology/Hematology, 120, 22–33. - PubMed
-
- Akbari, H. , Kazerooni, A. F. , Ware, J. B. , Mamourian, E. , Anderson, H. , Guiry, S. , Sako, C. , Raymond, C. , Yao, J. , Brem, S. , O'Rourke, D. M. , Desai, A. S. , Bagley, S. J. , Ellingson, B. M. , Davatzikos, C. , & Nabavizadeh, A. (2021). Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. Scientific Reports, 11(1), 15011. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical